← Volver a resultados
Ficha bibliográfica · Consulta y acceso
Artículo

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Bertram Pitt; Faı̈ez Zannad; Willem J. Remme; Robert Cody; A Castaigne; A.J. Pérez Pérez; Jolie Palensky; Janet Wittes · New England Journal of Medicine · 1999

Página del recurso
Lectura rápida. Revisá los datos básicos del recurso y luego accedé al contenido desde el botón principal. En esta ficha solo se muestra la información necesaria para identificar la obra, citarla y abrirla.

Acceso al recurso

Entrá al contenido desde la opción principal o elegí otra fuente disponible.

Acceso principal

Página del recurso

Página de referencia del recurso. El texto completo no está confirmado automáticamente.
Abrir recurso

Resumen

Descripción general del contenido del recurso.

BACKGROUND AND METHODS: Aldosterone is important in the pathophysiology of heart failure. In a doubleblind study, we enrolled 1663 patients who had severe heart failure and a left ventricular ejection fraction of no more than 35 percent and who were being treated with an angiotensin-converting-enzyme inhibitor, a loop diuretic, and in most cases digoxin. A total of 822 patients were randomly assigned to receive 25 mg of spironolactone daily, and 841 to receive placebo. The primary end point was death from all causes. RESULTS: The trial was discontinued early, after a mean follow-up period of 24 months, because an interim analysis determined that spironolactone was efficacious. There were 386 deaths in the placebo group (46 percent) and 284 in the spironolactone group (35 percent; relative risk of death, 0.70; 95 percent confidence interval, 0.60 to 0.82; P<0.001). This 30 percent reduction in the risk of death among patients in the spironolactone group was attributed to a lower risk of both death from progressive heart failure and sudden death from cardiac causes. The frequency of hospitalization for worsening heart failure was 35 percent lower in the spironolactone group than in the placebo group (relative risk of hospitalization, 0.65; 95 percent confidence interval, 0.54 to 0.77; P<0.001). In addition, patients who received spironolactone had a significant improvement in the symptoms of heart failure, as assessed on the basis of the New York Heart Association functional class (P<0.001). Gynecomastia or breast pain was reported in 10 percent of men who were treated with spironolactone, as compared with 1 percent of men in the placebo group (P<0.001). The incidence of serious hyperkalemia was minimal in both groups of patients. CONCLUSIONS: Blockade of aldosterone receptors by spironolactone, in addition to standard therapy, substantially reduces the risk of both morbidity and death among patients with severe heart failure.

Cómo citar

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

Pitt, B, Zannad, F, Remme, W. J, Cody, R, Castaigne, A, Pérez, A. P, Palensky, J, & Wittes, J. (1999). The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. https://doi.org/10.1056/nejm199909023411001

MLA

Pitt, Bertram, et al. "The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure." 1999. https://doi.org/10.1056/nejm199909023411001.

Chicago

Pitt, Bertram, Faı̈ez Zannad, Willem J. Remme, Robert Cody, A Castaigne, A.J. Pérez Pérez, Jolie Palensky, and Janet Wittes. 1999. "The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure.". https://doi.org/10.1056/nejm199909023411001.

Harvard

Pitt, B. et al. 1999, The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure, New England Journal of Medicine, available at: https://doi.org/10.1056/nejm199909023411001 [Accessed 29 Jun. 2026].

Compartir e imprimir

Guardá la ficha, copiá su enlace permanente o imprimila como PDF.

Exportar referencia

Si usás un gestor bibliográfico, podés exportar el registro en los formatos más comunes.

Detalles del recurso

Información bibliográfica útil para confirmar que se trata del material correcto.

Título
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Autor / colaboradores
Bertram Pitt; Faı̈ez Zannad; Willem J. Remme; Robert Cody; A Castaigne; A.J. Pérez Pérez; Jolie Palensky; Janet Wittes
Editorial
New England Journal of Medicine
Año de publicación
1999
Idioma
en

Materias

Explorá otros recursos relacionados a partir de estas materias.

Copiado